112 related articles for article (PubMed ID: 2529084)
41. [Changes of the biohumoral picture in alcoholic hepatopathy treated with thiazolidinecarboxylate of arginine].
Zotti S; Bergamo S; Maddalosso T; Salmi A
Arch Sci Med (Torino); 1979; 136(3):363-8. PubMed ID: 44995
[TBL] [Abstract][Full Text] [Related]
42. Improvement of the complex medical treatment for the patients wіth chronic biliary pancreatitis.
Babinets LS; Kytsai KY; Kotsaba YY; Halabitska IM; Melnyk NA; Semenova IV; Zemlyak OS
Wiad Lek; 2017; 70(2):213-216. PubMed ID: 28511162
[TBL] [Abstract][Full Text] [Related]
43. Pyridoxol L,2-pyrrolidon-5 carboxylate prevents active fibroplasia in CCl4-treated rats.
Annoni G; Contu L; Tronci MA; Caputo A; Arosio B
Pharmacol Res; 1992 Jan; 25(1):87-93. PubMed ID: 1310810
[TBL] [Abstract][Full Text] [Related]
44. [Tolerance of nitrefazole in alcoholics with liver disease. A 4-week placebo-controlled double-blind study].
Feuerlein W; Heesch D; Schmidt L; Werner HP; Bethge H; Görtelmeyer R
Fortschr Med; 1984 Apr; 102(14):409-13. PubMed ID: 6144620
[TBL] [Abstract][Full Text] [Related]
45. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH).
Fehér J; Lengyel G
J Int Med Res; 2003; 31(6):537-51. PubMed ID: 14708419
[TBL] [Abstract][Full Text] [Related]
46. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin.
Hock B; Schwarz M; Domke I; Grunert VP; Wuertemberger M; Schiemann U; Horster S; Limmer C; Stecker G; Soyka M
Addiction; 2005 Oct; 100(10):1477-86. PubMed ID: 16185209
[TBL] [Abstract][Full Text] [Related]
47. [The use of reduced glutathione in alcoholic hepatopathy].
Bresci G; Piccinocchi M; Banti S
Minerva Med; 1991 Nov; 82(11):753-5. PubMed ID: 1766577
[TBL] [Abstract][Full Text] [Related]
48. [High-dose reduced glutathione in the therapy of alcoholic hepatopathy].
Nardi EA; Devito R; Tiburzi F; Ceccanti M
Clin Ter; 1991 Jan; 136(1):47-51. PubMed ID: 1826873
[TBL] [Abstract][Full Text] [Related]
49. [Reproductive toxicity of metadoxine in rats].
Wang Y; Zhu HJ; Lai WQ; Chen JG; Mei S; Zhang WY; Zhang X
Zhonghua Yu Fang Yi Xue Za Zhi; 2003 May; 37(3):178-82. PubMed ID: 12880564
[TBL] [Abstract][Full Text] [Related]
50. The hepatic component in alcoholic encephalopathy.
Banciu T; Weidenfeld H; Wilham V; Berinde L; David P; Sgăvirdea C; Ocica I
Med Interne; 1982; 20(1):67-71. PubMed ID: 7123107
[TBL] [Abstract][Full Text] [Related]
51. [A controlled clinical study on the efficacy and tolerability of stepronin in chronic alcoholic liver diseases].
De Rensis L; Schianchi L; Assunto A; Antenora G; Allocca F; Bossone V
Clin Ter; 1990 Nov; 135(3):209-13. PubMed ID: 2150022
[TBL] [Abstract][Full Text] [Related]
52. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.
Higuera-de la Tijera F; Servín-Caamaño AI; Serralde-Zúñiga AE; Cruz-Herrera J; Pérez-Torres E; Abdo-Francis JM; Salas-Gordillo F; Pérez-Hernández JL
World J Gastroenterol; 2015 Apr; 21(16):4975-85. PubMed ID: 25945012
[TBL] [Abstract][Full Text] [Related]
53. Effects of metadoxine on cellular free fatty acid levels in ethanol treated rats.
Calabrese V; Bombaci G; Calderone A; Rizza V
Int J Tissue React; 1993; 15(6):235-43. PubMed ID: 8088945
[TBL] [Abstract][Full Text] [Related]
54. Application of stability-indicating HPTLC method for quantitative determination of metadoxine in pharmaceutical dosage form.
Kaul N; Agrawal H; Patil B; Kakad A; Dhaneshwar SR
Farmaco; 2005 Apr; 60(4):351-60. PubMed ID: 15848212
[TBL] [Abstract][Full Text] [Related]
55. Ethanol-induced dysfunction of hepatocytes and leukocytes in patients without liver failure.
Gheorghiu M; Bâră C; Păsărică D; Braşoveanu L; Bleotu C; Topârceanu F; Trandafir T; Diaconu CC
Roum Arch Microbiol Immunol; 2004; 63(1-2):5-33. PubMed ID: 16295318
[TBL] [Abstract][Full Text] [Related]
56. [Role of metadoxyl in the treatment of the hepatotoxic effects of cytostatics].
Safonova SA; Gershanovich ML
Vopr Onkol; 2005; 51(5):599-600. PubMed ID: 16756021
[No Abstract] [Full Text] [Related]
57. Effect of metadoxine on striatal dopamine levels in C57 black mice.
Fornai F; Grazia Alessandrì M; Bonuccelli U; Scalori V; Corsini GU
J Pharm Pharmacol; 1993 May; 45(5):476-8. PubMed ID: 8099970
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of metadoxine for injection after repeated doses in healthy volunteers.
Lü Y; Kang ZS; Liu Y; Li TY; Xiao YH
Chin Med J (Engl); 2007 Jan; 120(2):166-8. PubMed ID: 17335665
[No Abstract] [Full Text] [Related]
59. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
Gillet C; Polard E; Mauduit N; Allain H
Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
[TBL] [Abstract][Full Text] [Related]
60. Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Borro P; Leone S; Testino G
Curr Drug Targets; 2016; 17(2):239-51. PubMed ID: 25981604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
